Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

RASRx

RASRx
2014 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
2 INVESTORS
Description

Developer of system biology therapies designed for the treatment of rare diseases. The company's system biology therapies mutation independent approach to slowing and potentially reversing disease progression to bring relief to patients with Duchenne, and possibly other muscular dystrophies, providing physicians with complex muscle pathology for the treatment of duchenne muscular dystrophy.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 231 Bonetti Drive
  • Suite 240
  • San Luis Obispo, CA 93401
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore RASRx’s full profile, request a free trial.

RASRx Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 06-Jan-2016 Completed Startup
1. Grant 11-Nov-2015 000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

RASRx Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
CureDuchenne Ventures Corporate Venture Capital Minority 000 0000 000000 0
United States Department of Defense Government 000 0000 000000 0

RASRx Executive Team (1)

Name Title Board
Seat
Contact
Info
Kathleen Rodgers Co-Founder